Page 4 - Zai Lab Forward News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomUnited statesRafaelg amadoChristine chiou lina zhangShaun maccoun xiaoyu chenZai lab limitedBristol myers squibbNational medical products administrationPoint therapeutics incHead of global oncology researchZai lab forwardZai labExchange commissionDrug administrationLab limited

MIL-OSI: Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates

MIL-OSI: Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine chiou lina zhangBristol myers squibbJosh smileyShaun maccoun xiaoyu chenAsia pacificBilly choNovocure limitedRegeneron pharmaceuticals incInnoviva incData monitoring committeeZai lab forwardMirati therapeutics incNational medical products administrationExchange commission

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55% .

Hong kongUnited statesUnited kingdomAlina zhangShaun maccounXiaoyu chenChristine chiouRafaelg amadoHead of global oncology researchZai lab forwardZai lab limitedExchange commissionZai labLab limitedGlobal oncology researchAbout ovarian

MIL-OSI: JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

MIL-OSI: JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomShaun maccounRafaelg amadoXiaoyu chenAlina zhangChristine chiouZai lab forwardZai labExchange commissionHead of global oncology researchZai lab limitedRecommended sponsor painted moonOriginal artwork directlyGlobal oncology research

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Study met primary endpoint ; VYVGART® Hytrulo demonstrated 61% reduction in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology.

United kingdomUnited statesHong kongAlina zhangShaun maccoun xiaoyu chenChristine chiouHarald reinhartDemyelinating polyneuropathyGroup of huashan rare disease centerExchange commissionHead of global developmentDepartment of neurologyZai lab limitedZai lab forwardZai labHuashan hospital affiliated to fudan university